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Aim.The aim of our study was to assess whether selected single nucleotide polymorphisms ofCYP1A1 and 2E1,GSTM1,GSTT1, and
SULT1A1 influence susceptibility towards HCC, considering their interaction with cigarette smoking.Methods. We recruited HCC
cases and controls among patients admitted to the hospital “Agostino Gemelli,” from January 2005 until July 2010. Odds ratios (OR)
of HCC were derived from unconditional multiple logistic regression. Gene-gene and gene-smoking interaction were quantified
by computing the attributable proportion (AP) due to biological interaction. Results. The presence of any CYP2E1∗5B variant allele
(OR: 0.23; 95% CI: 0.06-0.71) and CYP2E1∗6 variant allele (OR: 0.08; 95% CI: 0.01–0.33) was inversely related to HCC. There was
a borderline increased risk among carriers of combined CYP1A1∗2A and SULT1A1 variant alleles (OR: 1.67; 95% CI: 0.97–3.24). A
significant biological interaction was observed between GSTT1 and smoking (AP = 0.48; 95% CI: 0.001–0.815), with an OR of 3.13
(95% CI: 1.69–5.82), and borderline significant interaction was observed for SULT1A1 and smoking (AP = 0.36; 95% CI: −0.021–
0.747), with an OR of 3.05 (95% CI: 1.73–5.40). Conclusion. CYP2E1∗5B and CYP2E1∗6 polymorphisms have a favourable effect
on the development of HCC, while polymorphisms of GSTT1 and SULT1A1might play role in increasing the susceptibility among
smokers.
1. Introduction
Hepatocellular carcinoma (HCC) is currently the sixth most
common cancer and the third cause of cancer deaths world-
wide [1]. Its prognosis remains poor, with a 5-year survival
rate less than 20% in Europe [2]. Risk factors for HCC
include infection with hepatitis B (HBV) and hepatitis C
viruses (HCV), history of diabetes mellitus, nonalcoholic
fatty liver disease and cirrhosis, heavy alcohol consumption,
and cigarette smoking [3–5]. Coffee consumption appears to
have a favorable effect [6]. Further, genetic factors appear to
modulate the individual susceptibility as the siblings of HCC
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individuals are more prone to develop the HCC even in the
absence of HBV infection [7]. So far, several single nucleotide
polymorphisms (SNPs) have been investigated in association
with HCC, with contradictory results [8].
As the liver is the main metabolic organ, the SNPs
related to genes encoding carcinogen-metabolizing enzymes
represent key target candidates for association analyses.
Cytochrome P-450 (CYP) is a superfamily of monooxyge-
nases responsible for phase I enzyme reactions, preparing
substrates for phase II conjugation reactions, but they can
also lead to the metabolic activation of toxic or carcinogenic
compounds [9]. The glutathione S-transferases (GSTs) are
a gene superfamily coding phase II enzymes that detoxify
free radicals in tobacco smoke, products of oxidative stress,
and polycyclic aromatic hydrocarbons [10]. Sulfotransferase
(SULT) catalyzes sulfonate conjugation to detoxify the pro-
carcinogens to metabolites, which are easily eliminated from
the body [11]. Polymorphisms in these genes, their combi-
nation, and interaction with environmental factors have the
potential to lead to increased susceptibility to HCC. While
some studies investigated the effect of GST and CYP genes
on HCC, as well as their combination and interaction with
smoking [12, 13], little information is available on the effect of
SULT1A1.
The aim of our study was to assess whether the selected
SNPs ofCYP1A1 and 2E1,GSTM1, GSTT1, and SULT1A1 genes
influence individual susceptibility to HCC, also considering
their combination and interaction with cigarette smoking.
2. Methods
2.1. Study Population. Study participants were recruited
among patients admitted to the teaching hospital “Agostino
Gemelli” of the Universita` Cattolica del Sacro Cuore (Rome,
Italy) from January 2005 until July 2010, and eligibility was
restricted to white individuals born in Italy. Cases were 221
patients with HCC recruited among subjects referred to the
Outpatient Liver Unit of the hospital. The diagnosis of HCC
was performed according the AASLD guidelines [14]. The
control group included 290 patients from the same hospital
with a broad range of diagnoses, enrolled during the same
time period. In closer detail, around 50% of the controls
were outpatients, and the remaining were patients under-
going surgical interventions (laparoscopic cholecystectomy,
appendicitis, and inguinal hernia) or admitted for a wide
spectrum of other nonneoplastic conditions (elderly patients
on physical-therapy rehabilitation after stroke or orthopedic
injuries). Written informed consent was obtained from all
study subjects. The study was conducted according to the
Declaration of Helsinki and was approved by the Ethical
Committee of Universita` Cattolica del Sacro Cuore.
HCC cases and controls were interviewed by trained
physicians using a structured questionnaire to collect infor-
mation on demographics, medical history, and lifestyle habits
including smoking history. Questions about lifestyle habits
focused on the time period ending one year prior to diagnosis
for cases and on the year prior to the interview date for
controls.
Table 1: Distribution of 221 cases of hepatocellular carcinoma
(HCC) and 290 controls according to selected factors.
HCC cases (𝑁 = 221) Controls (𝑁 = 290)
𝑁 (%) 𝑁 (%)
Age (years)
<60 43 (19.5) 105 (36.2)
60–69 80 (36.2) 78 (26.9)
≥70 98 (44.3) 107 (36.9)
Sex
Male 160 (72.4) 176 (60.7)
Female 61 (27.6) 114 (39.3)
Smokinga
Never 85 (39.2) 173 (59.7)
Ever 133 (60.8) 117 (40.3)
𝑃
b
< 0.001
Hepatitisa,c
No 64 (29.0) 282 (97.9)
Yes 157 (71.0) 6 (2.1)
𝑃
b
< 0.001
a
The sum does not add up to the total because of some missing values.
b
𝑃 values from 𝜒2 test.
cHepatitis was defined as history of hepatitis B and/or C.
2.2. Genotyping Methods. DNA was extracted from the
peripheral blood lymphocytes of each participating
subject. GSTM1 and GSTT1 null alleles were identified
using a multiplex-polymerase chain reaction- (PCR-)
based method [15]. The polymorphic site at nucleotide
638 in exon 7 (Arg213His (∗2 allele), rs9282861) of the
SULT1A1 gene was genotyped by PCR-restriction fragment
length polymorphisms (RFLP) analysis as described by
Coughtrie et al. [16]. CYP1A1 3󸀠-flanking region MspI poly-
morphism (CYP1A1∗2A allele, rs4646903), CYP2E1 PstI/RsaI
polymorphism (CYP2E1∗5B allele, rs3813867 (PstI)), and
CYP2E1 DraI (∗5A or ∗6 alleles, rs6413432) were also
determined by PCR-RFLP analyses. Quality control for each
genotyping was performed in each experiment, and 10% of
the total samples were randomly selected and reanalyzed
with 100% concordance. All laboratory procedures were
carried out blindly to case-control status.
2.3. Statistical Analysis. Hardy-Weinberg equilibrium
(HWE) was tested for the control SNPs. Odds ratios (OR)
of HCC and corresponding 95% confidence intervals (CI)
according to analyzed polymorphisms were derived from
unconditional multiple logistic regression models [17] using
dominant model for carriers of the mutated allele, including
terms for age and sex. When cell sizes were small (<5), exact
logistic regression was used [18].
We also examined the possible confounding effect of
smoking, alcohol, and chronic infection with HBV and/or
HCV. However, models including these covariates yielded
very similar results; thus, given the small numbers in some
strata, only the age- and sex-adjusted estimates were pre-
sented.
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Table 2: Distribution of cases and controls, odds ratiosa (OR), and 95% confidence intervals (CI) for hepatocellular carcinoma (HCC)
according to selected polymorphisms.
HCC cases (𝑁 = 221) Controls (𝑁 = 290) OR (95% CI)
𝑁 (%) 𝑁 (%)
CYP1A1∗2A
wt/wt 165 (74.7) 226 (77.9) 1b
wt/mt and mt/mt 56 (25.3) 64 (22.7) 1.21 (0.80–1.84)
CYP2E1∗5B
𝑐1/𝑐1 217 (98.2) 270 (93.1) 1b
𝑐1/𝑐2 and 𝑐2/𝑐2 4 (1.8) 20 (6.9) 0.23 (0.06–0.71)
CYP2E1∗6c
wt/wt 204 (99.0) 261 (90.0) 1d
wt/mt and mt/mt 2 (1.0) 29 (10.0) 0.08 (0.01–0.33)
GSTM1c
Present 96 (47.8) 139 (48.1) 1b
Null 105 (52.2) 150 (51.9) 0.99 (0.68–1.43)
GSTT1c
Present 141 (70.1) 220 (76.1) 1b
Null 60 (29.9) 69 (23.9) 1.35 (0.89–2.05)
SULT1A1
wt/wt 132 (59.7) 180 (62.1) 1b
wt/mt and mt/mt 89 (40.3) 110 (37.9) 1.22 (0.84–1.77)
aAdjusted for age and sex.
bReference category.
cThe sum does not add up to the total because of some missing values.
dCalculated from exact logistic regression analysis.
wt: wild-type allele.
mt: variant-type allele.
Gene-gene interaction analysis was conducted, using as
a reference group the homozygous wild-type individuals for
both genes, while for gene-environment interaction anal-
yses, the reference group was wild-type homozygotes not
exposed to the environmental risk factor. Biological interac-
tion between two genes was estimated using departure from
additivity of effects as the criterion of interaction, as proposed
by Rothman [19]. To quantify the amount of interaction,
the attributable proportion (AP) due to interaction was
calculated togetherwith its 95%CI as described byAndersson
et al. [20]. The AP due to interaction is the proportion
of individuals among those exposed to the two interacting
factors that is attributable to the interaction per se and it is
equal to 0 in the absence of a biological interaction [19]. In
order to test for more than multiplicative effect among two
genes, the likelihood ratio test was used.
The paper has been written according to the STREGA
guidelines [21].
3. Results
The demographics, clinical features and lifestyle habits of 221
HCC cases and 290 controls are reported in Table 1. Ever
smokersweremore common among cases, aswell as infection
with HBV and/or HCV (Table 1). The genotype frequencies
were in HWE (𝑃 > 0.05).
Table 2 reports the distribution of the polymorphisms
considered amongHCC patients and controls.The carriers of
c2 variant allele ofCYP2E1∗5Bpolymorphismswere less com-
mon in cases (1.8%) than in controls (6.9%) corresponding to
an OR of 0.23 (95% CI: 0.06–0.71). Similarly, the frequency
of the variant allele of CYP2E1∗6 polymorphism was also
less common among cases (1.0%) than controls (10%), with
an OR of 0.08 (95% CI: 0.01–0.33) (Table 2). The selected
polymorphisms ofCYP1A1,GSTM1,GSTT1, and SULT1A1 did
not significantly influence susceptibility to HCC.
The gene-gene and gene-smoking interaction results
are reported in Tables 3 and 4. We observed a border-
line increased risk for HCC among carriers of combined
CYP1A1∗2A and SULT1A1 variant alleles as compared to
the double wild-type homozygotes (OR = 1.67; 95% CI:
0.97–3.24) (Table 3). A significant interaction was reported
between GSTT1 and smoking (AP = 0.48; 95% CI: 0.001–
0.815), with an OR of 3.13 (95% CI: 1.69–5.82) for GSTT1 null
genotype carriers who were smokers (Table 4). A borderline
significant interaction was also observed for SULT1A1 and
smoking (AP = 0.36; 95% CI: −0.021–0.747), with an OR
of 3.05 (95 CI: 1.73–5.40) for those SULT1A1 variant allele
carriers who were smokers (Table 4).
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Table 3: Effect of the genes-gene interaction on the development of hepatocellular carcinoma.
Cases : controls ORa (95% CI) 𝑃b AP (95% CI)
GSTM1 × CYP1A1∗2A
Present/wt homozygote 74 : 113 1c
Null/wt homozygote 78 : 112 1.05 (0.69–1.61)
Present/any mt 22 : 26 1.32 (0.69–2.53)
Null/any mt 27 : 38 1.04 (0.58–1.88) 0.521 nc
GSTM1 × GSTT1
Present/present 66 : 103 1c
Null/present 75 : 117 0.97 (0.63–1.50)
Present/null 30 : 36 1.28 (0.71–2.30)
Null/null 30 : 33 1.39 (0.77–2.53) 0.773 0.109 (−0.603; 0.820)
GSTM1 × SULT1A1
Present/present 53 : 84 1c
Null/present 67 : 96 1.09 (0.68–1.76)
Present/null 43 : 55 1.40 (0.81–2.41)
Null/null 38 : 54 1.22 (0.70–2.13) 0.566 nc
GSTT1 × CYP1A1∗2A
Present/wt homozygote 108 : 169 1c
Null/wt homozygote 44 : 56 1.20 (0.74–1.93)
Present/any mt 33 : 51 0.98 (0.58–1.63)
Null/any mt 16 : 13 2.00 (0.91–4.41) 0.289 0.414 (−0.149; 0.976)
GSTT1 × SULT1A1
Present/wt/wt 81 : 138 1c
Null/wt/wt 39 : 42 1.59 (0.94–2.70)
Present/any mt 60 : 82 1.40 (0.90–2.20)
Null/any mt 21 : 27 1.48 (0.77–2.84) 0.347 nc
SULT1A1 × CYP1A1∗2A
wt homozygote/wt homozygote 99 : 138 1c
mt carrier/wt homozygote 66 : 88 1.14 (0.75–1.74)
wt homozygote/mt carrier 33 : 62 1.09 (0.64–1.85)
mt carrier/mt carrier 23 : 22 1.67 (0.97–3.24) 0.493 0.269 (−0.330; 0.867)
OR: odds ratio; CI: confidence interval; AP: attributable proportion; nc: not calculable.
aAdjusted for age and sex.
b
𝑃 from test for multiplicative interaction.
cReference category.
wt: wild-type allele.
mt: variant-type allele.
4. Discussion
Our study identified CYP2E1∗5B and CYP2E1∗6 variant
alleles associated with a reduced risk of HCC. There was
a borderline increased risk for HCC among carriers of
combined SULT1A1 and CYP1A1∗2A variant alleles. The
polymorphisms in GSTT1 and SULT1A1 are associated with
increased susceptibility to smoking-related HCC.
CYP2E1 can activate N-nitrosamines and benzene con-
tained in cigarette smoke [22] and is involved in alcohol-
mediated generation of oxidative stress [23]. The expression
of CYP2E1 correlates with the generation of hydroxyethyl
radicals and lipid peroxidation products [23]. The vari-
ant CYP2E1∗5B and CYP2E1∗6 alleles are associated with
increased transcription of CYP2E1 [24] that leads to devel-
opment of HCC by promoting carcinogenesis.No significant
association between CYP2E1∗6 and HCC was reported so
far [25, 26], while contradictory results were reported for
the CYP2E1∗5B variant allele [27–35]. A recent meta-analysis
did not find CYP2E1∗5B c2 allele to be associated with HCC
[36], also after stratifying among Asians and white. Studies
conducted among white individuals, however, were few [26,
30, 35] and included limited numbers of cases.
The favorable effect of both CYP2E1 polymorphisms
on HCC development is not consistent with the biological
premises implying a promoting role of a high activity enzyme.
However, the only study previously conducted in an Italian
population [35] on CYP2E1∗5B c2 allele and HCC did report
a similar association, indicating a favorable role of the variant
allele against HCC which deserves further investigation.
Our results suggest that up to 48% and 36% of HCC
cases among smokers carrying, respectively, variant GSTT1
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Table 4: Effect of the gene-smoking interaction on the development of hepatocellular carcinoma.
Cases : controls ORa (95% CI) 𝑃b AP (95% CI)
CYP1A1∗2A × smokingc
wt homozygote/no 65 : 136 1d
wt homozygote/yes 98 : 90 2.16 (1.29–3.36)
mt carrier/no 20 : 37 1.08 (0.58–2.03)
mt carrier/yes 35 : 27 2.81 (1.51–5.23) 0.680 0.201 (−0.328; 0.730)
GSTM1 × smokingc
Present/no 31 : 91 1d
Present/yes 62 : 48 4.01 (2.20–7.28)
Null/no 48 : 81 1.82 (1.05–3.18)
Null/yes 57 : 69 2.34 (1.32–4.23) 0.004 nc
GSTT1 × smokingc
Present/no 59 : 129 1d
Present/yes 81 : 91 1.86 (1.17–2.97)
Null/no 20 : 43 0.99 (0.53–1.86)
Null/yes 38 : 26 3.13 (1.69–5.82) 0.230 0.480 (0.001; 0.815)
SULT1A1 × smokingc
wt homozygote/no 52 : 103 1d
wt homozygote/yes 78 : 77 1.93 (1.19–3.14)
mt carrier/no 33 : 70 1.01 (0.59–1.75)
mt carrier/yes 55 : 40 3.05 (1.73–5.40) 0.250 0.363 (−0.021; 0.747)
OR: odds ratio; CI: confidence interval; AP: attributable proportion; nc: not calculable.
aAdjusted for age and sex.
b
𝑃 from test for multiplicative interaction.
cThe sum does not add up to the total because of some missing values.
dReference category.
wt: wild-type allele.
mt: variant-type allele.
and SULT1A1 alleles occurred because of gene-smoking
interaction. However, we could not further stratify these two
results according to quantity of smoking, as numbers were
low. Smoking is recognized as a risk factor forHCC [3–5] and,
together with HBV and HCV, one of the major risk factors
in Europe [37], and enzymes coded by GSTT1 and SULT1A1
have their role in the metabolism of tobacco carcinogens.
There is therefore a biological ground for possible synergic
carcinogenic effect.
There was a borderline synergic effect of SULT1A1 and
CYP1A1∗2A polymorphisms in HCC carcinogenesis. The
effect of SULT1A1 polymorphism on HCC development has
not been investigated so far. It has been reported, however,
that an enzyme coded by SULT1A1 variant allele has twofold
lower catalytic activity in detoxifying the procarcinogens
[38]. The biological significance of variant CYP1A1∗2A vari-
ant allele is uncertain, but CYP1A1∗2A has been reported
to increase susceptibility to several cancer types, including
lung, breast, and cervical cancer [39–41]. There is therefore
a rationale for a synergic effect of these two SNPs in HCC
carcinogenesis.
In our study, there was no significant association between
HCC and alcohol. As most of the cases have hepatitis,
this could lead them to stop drinking. Consequently we
were unable to perform gene-alcohol interaction analysis.
Secondly, we cannot exclude a selection bias. However, since
the observed frequencies of the variant alleles of CYP1A1∗2A,
as well as the null genotypes of GSTM1 and GSTT1, were in
line with those previously reported in the Italian population,
a major impact of such bias is unlikely [35, 42]. Thirdly, our
study was underpowered to perform gene-gene and gene-
interaction analysis.
In conclusion, we report that CYP2E1∗5B and CYP2E1∗6
polymorphisms have a favorable effect on the development of
HCC, while the polymorphisms in GSTT1 and SULT1A1may
increase HCC susceptibility among smokers.
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